Pediatric Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas), By Region and Competition, 2020-2030F
Market Overview
The Global Pediatric Clinical Trials Market was valued at USD 15.29 billion in 2024 and is projected t%li%reach USD 23.67 billion by 2030, growing at a CAGR of 7.56% during the forecast period. Pediatric clinical trials focus on assessing the safety, efficacy, and appropriate dosing of drugs, medical devices, and therapies for infants, children, and adolescents. These trials are vital for addressing medical conditions unique t%li%the pediatric population and ensuring age-appropriate treatments. Ethical considerations are paramount, with protocols involving informed consent from parents or guardians. Trials are structured t%li%measure outcomes such as symptom improvement, disease progression, and safety. Rising pediatric disease incidence, such as pneumonia, which affects over 1,400 children per 100,000 globally each year, underscores the urgent need for targeted therapies. Pharmaceutical companies are responding by prioritizing pediatric studies t%li%close treatment gaps, especially in high-burden regions like South Asia and Sub-Saharan Africa. Growing demand for specialized pediatric care and regulatory support further propels the market forward.
Key Market Drivers
Growing Focus on Rare Diseases
The increasing emphasis on rare or orphan diseases—many of which primarily affect children—is a major driver of pediatric clinical trials. With limited treatment options available, pediatric trials play a crucial role in drug development for these underserved conditions. Regulatory bodies such as the FDA and EMA incentivize this research through extended exclusivity periods, tax credits, and application fee waivers. Orphan drug designations can als%li%expedite development timelines and enhance funding opportunities. In addition, patient advocacy groups actively collaborate with stakeholders t%li%promote awareness and facilitate research efforts, thus boosting clinical trial activity in pediatric rare disease populations.
Key Market Challenges
Diversity and Representation
A major challenge in pediatric clinical trials is ensuring demographic diversity and inclusive representation. Without adequate participation from diverse racial, ethnic, and socioeconomic groups, trial results risk being non-generalizable and potentially biased. This underrepresentation can exacerbate healthcare disparities, particularly in conditions that disproportionately impact specific populations. Factors such as cultural differences, language barriers, and socioeconomic status can hinder participation, while the need for parental consent introduces additional complexity. Regulatory authorities increasingly emphasize inclusivity in trial design, and engagement with local communities is essential t%li%building trust and overcoming recruitment challenges. Culturally competent communication strategies are critical for improving representation across pediatric studies.
Key Market Trends
Increasing Emphasis on Pediatric Drug Development
There is a growing focus on developing pediatric-specific medications, driven by both commercial potential and public health need. Advances in genomics, targeted therapies, and precision medicine are creating new pathways for pediatric drug development. Collaborative networks like the Pediatric Trials Network and the International Neonatal Consortium are supporting these efforts by pooling resources and patient data. Patient advocacy groups and global health initiatives are further amplifying awareness and support for pediatric research. These developments are accelerating clinical trial activity and fostering innovation in pediatric therapeutics, especially in areas with historically limited treatment options.
Key Market Players
In this report, the Global Pediatric Clinical Trials Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.
Available Customizations:
Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
The Global Pediatric Clinical Trials Market was valued at USD 15.29 billion in 2024 and is projected t%li%reach USD 23.67 billion by 2030, growing at a CAGR of 7.56% during the forecast period. Pediatric clinical trials focus on assessing the safety, efficacy, and appropriate dosing of drugs, medical devices, and therapies for infants, children, and adolescents. These trials are vital for addressing medical conditions unique t%li%the pediatric population and ensuring age-appropriate treatments. Ethical considerations are paramount, with protocols involving informed consent from parents or guardians. Trials are structured t%li%measure outcomes such as symptom improvement, disease progression, and safety. Rising pediatric disease incidence, such as pneumonia, which affects over 1,400 children per 100,000 globally each year, underscores the urgent need for targeted therapies. Pharmaceutical companies are responding by prioritizing pediatric studies t%li%close treatment gaps, especially in high-burden regions like South Asia and Sub-Saharan Africa. Growing demand for specialized pediatric care and regulatory support further propels the market forward.
Key Market Drivers
Growing Focus on Rare Diseases
The increasing emphasis on rare or orphan diseases—many of which primarily affect children—is a major driver of pediatric clinical trials. With limited treatment options available, pediatric trials play a crucial role in drug development for these underserved conditions. Regulatory bodies such as the FDA and EMA incentivize this research through extended exclusivity periods, tax credits, and application fee waivers. Orphan drug designations can als%li%expedite development timelines and enhance funding opportunities. In addition, patient advocacy groups actively collaborate with stakeholders t%li%promote awareness and facilitate research efforts, thus boosting clinical trial activity in pediatric rare disease populations.
Key Market Challenges
Diversity and Representation
A major challenge in pediatric clinical trials is ensuring demographic diversity and inclusive representation. Without adequate participation from diverse racial, ethnic, and socioeconomic groups, trial results risk being non-generalizable and potentially biased. This underrepresentation can exacerbate healthcare disparities, particularly in conditions that disproportionately impact specific populations. Factors such as cultural differences, language barriers, and socioeconomic status can hinder participation, while the need for parental consent introduces additional complexity. Regulatory authorities increasingly emphasize inclusivity in trial design, and engagement with local communities is essential t%li%building trust and overcoming recruitment challenges. Culturally competent communication strategies are critical for improving representation across pediatric studies.
Key Market Trends
Increasing Emphasis on Pediatric Drug Development
There is a growing focus on developing pediatric-specific medications, driven by both commercial potential and public health need. Advances in genomics, targeted therapies, and precision medicine are creating new pathways for pediatric drug development. Collaborative networks like the Pediatric Trials Network and the International Neonatal Consortium are supporting these efforts by pooling resources and patient data. Patient advocacy groups and global health initiatives are further amplifying awareness and support for pediatric research. These developments are accelerating clinical trial activity and fostering innovation in pediatric therapeutics, especially in areas with historically limited treatment options.
Key Market Players
- Bristol-Myers Squibb Company
- Charles River Laboratories International Inc.
- Covance Inc.
- GlaxoSmithKline plc
- ICON plc
- IQVIA Inc.
- Novartis AG
- Pfizer, Inc.
- Pharmaceutical Product Development, LLC
- Syneos Health Inc.
- Paidion Research, Inc.
- The Emmes Company, LLC
In this report, the Global Pediatric Clinical Trials Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Pediatric Clinical Trials Market, By Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
- Pediatric Clinical Trials Market, By Study Design:
- Treatment Studies
- Observational Studies
- Pediatric Clinical Trials Market, By Therapeutic Area:
- Respiratory Disease
- Infectious Diseases
- Oncology
- Diabetes
- Other Therapeutic Areas
- Pediatric Clinical Trials Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.
Available Customizations:
Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
5.2.2. By Study Design (Treatment Studies and Observational Studies)
5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Phase
6.2.2. By Study Design
6.2.3. By Therapeutic Design
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Pediatric Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Phase
6.3.1.2.2. By Study Design
6.3.1.2.3. By Therapeutic Design
6.3.2. India Pediatric Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Phase
6.3.2.2.2. By Study Design
6.3.2.2.3. By Therapeutic Design
6.3.3. Australia Pediatric Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Phase
6.3.3.2.2. By Study Design
6.3.3.2.3. By Therapeutic Design
6.3.4. Japan Pediatric Clinical Trials Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Phase
6.3.4.2.2. By Study Design
6.3.4.2.3. By Therapeutic Design
6.3.5. South Korea Pediatric Clinical Trials Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Phase
6.3.5.2.2. By Study Design
6.3.5.2.3. By Therapeutic Design
7. EUROPE PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Phase
7.2.2. By Study Design
7.2.3. By Therapeutic Design
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Pediatric Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Phase
7.3.1.2.2. By Study Design
7.3.1.2.3. By Therapeutic Design
7.3.2. Germany Pediatric Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Phase
7.3.2.2.2. By Study Design
7.3.2.2.3. By Therapeutic Design
7.3.3. Spain Pediatric Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Phase
7.3.3.2.2. By Study Design
7.3.3.2.3. By Therapeutic Design
7.3.4. Italy Pediatric Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Phase
7.3.4.2.2. By Study Design
7.3.4.2.3. By Therapeutic Design
7.3.5. United Kingdom Pediatric Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Phase
7.3.5.2.2. By Study Design
7.3.5.2.3. By Therapeutic Design
8. NORTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Phase
8.2.2. By Study Design
8.2.3. By Therapeutic Design
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Pediatric Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Phase
8.3.1.2.2. By Study Design
8.3.1.2.3. By Therapeutic Design
8.3.2. Mexico Pediatric Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Phase
8.3.2.2.2. By Study Design
8.3.2.2.3. By Therapeutic Design
8.3.3. Canada Pediatric Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Phase
8.3.3.2.2. By Study Design
8.3.3.2.3. By Therapeutic Design
9. SOUTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Phase
9.2.2. By Study Design
9.2.3. By Therapeutic Design
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pediatric Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Phase
9.3.1.2.2. By Study Design
9.3.1.2.3. By Therapeutic Design
9.3.2. Argentina Pediatric Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Phase
9.3.2.2.2. By Study Design
9.3.2.2.3. By Therapeutic Design
9.3.3. Colombia Pediatric Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Phase
9.3.3.2.2. By Study Design
9.3.3.2.3. By Therapeutic Design
10. MIDDLE EAST AND AFRICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Phase
10.2.2. By Study Design
10.2.3. By Therapeutic Design
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pediatric Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Phase
10.3.1.2.2. By Study Design
10.3.1.2.3. By Therapeutic Design
10.3.2. Saudi Arabia Pediatric Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Phase
10.3.2.2.2. By Study Design
10.3.2.2.3. By Therapeutic Design
10.3.3. UAE Pediatric Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Phase
10.3.3.2.2. By Study Design
10.3.3.2.3. By Therapeutic Design
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. Bristol-Myers Squibb Company
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.. SWOT Analysis
16.2. Charles River Laboratories International Inc.
16.3. Covance Inc.
16.4. GlaxoSmithKline plc
16.5. ICON plc
16.6. IQVIA Inc.
16.7. Novartis AG
16.8. Pfizer, Inc.
16.9. Pharmaceutical Product Development, LLC
16.10.Syneos Health Inc.
16.11.Paidion Research, Inc.
16.12.The Emmes Company, LLC
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
5.2.2. By Study Design (Treatment Studies and Observational Studies)
5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. ASIA PACIFIC PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Phase
6.2.2. By Study Design
6.2.3. By Therapeutic Design
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Pediatric Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Phase
6.3.1.2.2. By Study Design
6.3.1.2.3. By Therapeutic Design
6.3.2. India Pediatric Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Phase
6.3.2.2.2. By Study Design
6.3.2.2.3. By Therapeutic Design
6.3.3. Australia Pediatric Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Phase
6.3.3.2.2. By Study Design
6.3.3.2.3. By Therapeutic Design
6.3.4. Japan Pediatric Clinical Trials Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Phase
6.3.4.2.2. By Study Design
6.3.4.2.3. By Therapeutic Design
6.3.5. South Korea Pediatric Clinical Trials Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Phase
6.3.5.2.2. By Study Design
6.3.5.2.3. By Therapeutic Design
7. EUROPE PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Phase
7.2.2. By Study Design
7.2.3. By Therapeutic Design
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Pediatric Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Phase
7.3.1.2.2. By Study Design
7.3.1.2.3. By Therapeutic Design
7.3.2. Germany Pediatric Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Phase
7.3.2.2.2. By Study Design
7.3.2.2.3. By Therapeutic Design
7.3.3. Spain Pediatric Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Phase
7.3.3.2.2. By Study Design
7.3.3.2.3. By Therapeutic Design
7.3.4. Italy Pediatric Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Phase
7.3.4.2.2. By Study Design
7.3.4.2.3. By Therapeutic Design
7.3.5. United Kingdom Pediatric Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Phase
7.3.5.2.2. By Study Design
7.3.5.2.3. By Therapeutic Design
8. NORTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Phase
8.2.2. By Study Design
8.2.3. By Therapeutic Design
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Pediatric Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Phase
8.3.1.2.2. By Study Design
8.3.1.2.3. By Therapeutic Design
8.3.2. Mexico Pediatric Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Phase
8.3.2.2.2. By Study Design
8.3.2.2.3. By Therapeutic Design
8.3.3. Canada Pediatric Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Phase
8.3.3.2.2. By Study Design
8.3.3.2.3. By Therapeutic Design
9. SOUTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Phase
9.2.2. By Study Design
9.2.3. By Therapeutic Design
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pediatric Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Phase
9.3.1.2.2. By Study Design
9.3.1.2.3. By Therapeutic Design
9.3.2. Argentina Pediatric Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Phase
9.3.2.2.2. By Study Design
9.3.2.2.3. By Therapeutic Design
9.3.3. Colombia Pediatric Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Phase
9.3.3.2.2. By Study Design
9.3.3.2.3. By Therapeutic Design
10. MIDDLE EAST AND AFRICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Phase
10.2.2. By Study Design
10.2.3. By Therapeutic Design
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pediatric Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Phase
10.3.1.2.2. By Study Design
10.3.1.2.3. By Therapeutic Design
10.3.2. Saudi Arabia Pediatric Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Phase
10.3.2.2.2. By Study Design
10.3.2.2.3. By Therapeutic Design
10.3.3. UAE Pediatric Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Phase
10.3.3.2.2. By Study Design
10.3.3.2.3. By Therapeutic Design
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE ANALYSIS
16. COMPETITIVE LANDSCAPE
16.1. Bristol-Myers Squibb Company
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.. SWOT Analysis
16.2. Charles River Laboratories International Inc.
16.3. Covance Inc.
16.4. GlaxoSmithKline plc
16.5. ICON plc
16.6. IQVIA Inc.
16.7. Novartis AG
16.8. Pfizer, Inc.
16.9. Pharmaceutical Product Development, LLC
16.10.Syneos Health Inc.
16.11.Paidion Research, Inc.
16.12.The Emmes Company, LLC
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
